About £3.7 million ($4.9 million) of proceeds from the placement would go toward the acquisition, while remaining funds will support assay development validation, and working capital.
The blood-based test is based on three serum biomarkers —matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion molecule-1.
Axela and Hutman Diagnostics have announced an agreement that will deliver a microarray-based, sample-to-answer pathogen detection platform to market next year.
NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.
NEW YORK (GenomeWeb News) – Multiplex instrument developer Axela today announced the hiring of investment bank AmeriTech Advisors to explore strategic opportunities for the firm.
Axela and OvaGene Oncology this week announced a partnership that will see OvaGene's gene signatures related to ovarian cancer treatment become available on Axela's Ziplex array platform.
NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.
